MedPath

LILLY SA

🇪🇸Spain
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.lilly.es

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

86

CIMA_AEMPS:67
NMPA:16
PHILIPPINES:2
+1 more agencies

Drug Approvals

Atomoxetine Hydrochloride Oral Solution

Product Name
盐酸托莫西汀口服溶液
Approval Number
国药准字HJ20180057
Approval Date
Oct 17, 2023
NMPA

Atomoxetine Hydrochloride Capsules

Product Name
择思达
Approval Number
国药准字HJ20160112
Approval Date
Aug 13, 2020
NMPA

Atomoxetine Hydrochloride Capsules

Product Name
择思达
Approval Number
国药准字HJ20160121
Approval Date
Aug 13, 2020
NMPA

Atomoxetine Hydrochloride Capsules

Product Name
择思达
Approval Number
国药准字HJ20160119
Approval Date
Aug 13, 2020
NMPA

Atomoxetine Hydrochloride Capsules

Product Name
择思达
Approval Number
国药准字HJ20160117
Approval Date
Aug 13, 2020
NMPA

Atomoxetine Hydrochloride Capsules

Product Name
择思达
Approval Number
国药准字HJ20160116
Approval Date
Aug 13, 2020
NMPA

Atomoxetine Hydrochloride Capsules

Product Name
择思达
Approval Number
国药准字HJ20160123
Approval Date
Aug 13, 2020
NMPA

Atomoxetine Hydrochloride Capsules

Product Name
择思达
Approval Number
国药准字HJ20160118
Approval Date
Aug 13, 2020
NMPA

Atomoxetine Hydrochloride Capsules

Product Name
择思达
Approval Number
国药准字HJ20160120
Approval Date
Aug 13, 2020
NMPA

Atomoxetine Hydrochloride Capsules

Product Name
择思达
Approval Number
国药准字HJ20160114
Approval Date
Aug 13, 2020
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.